Literature DB >> 8927460

Early versus late identification of infants at high risk of developing moderate to severe bronchopulmonary dysplasia.

H J Rozycki1, L Narla.   

Abstract

We developed a simple method to identify neonates at high risk of bronchopulmonary dysplasia (BPD) and determined whether early (8 hours) and late (14 days) risk assessment is equally useful. A retrospective cohort design was utilized of subjects enrolled in multi-dose surfactant trials to develop each risk identification model. Prospective testing of the late 14-day model was done to determine accuracy. The primary outcome variable (moderate to severe BPD) was defined as the need for oxygen and mechanical ventilation beyond 28 days of life and significant chest X-ray changes. Variables were screened for inclusion in the models by univariate and multiple regression analysis of data available at 14 days or 8 hours of life, converted to yes-no variables by the use of receiver-operator curves; the final model was based on those variables that gave the highest sensitivity and specificity for identifying BPD risk. Thirty-eight out of 116 of the 14-day model subjects developed BPD. The 14-day model (F1O2 > or = 0.30 and ventilation index (defined as 10,000/peak pressure x rate x PCO2) < 0.510 (or < 0.800 if previously septic)] had a sensitivity of 82% and specificity of 89%. It accurately identified 83% of cases (51/61) during at 1-year prospective test. The positive predictive value was 81% and negative predictive value 88%. Forty-four of the 698 early 8-hour model subjects developed BPD. The 8-hour model [gestational age < 31 weeks, 5-minute Apgar < 9, ventilator rate > 23 breaths/min, and ventilation index < 0.895] had a sensitivity of 73%, specificity of 83%, negative predictive value of 98% but positive predictive value of only 22%. These observation indicated that clinical data can create an accurate and simple model to classify infants into high- or low-risk groups for BPD. Using such models very early in life (e.g., at 8 hours) may lead to a high number of false-positive identifications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8927460     DOI: 10.1002/(SICI)1099-0496(199606)21:6<345::AID-PPUL1>3.0.CO;2-K

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  5 in total

1.  Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants.

Authors:  Matthew M Laughon; John C Langer; Carl L Bose; P Brian Smith; Namasivayam Ambalavanan; Kathleen A Kennedy; Barbara J Stoll; Susie Buchter; Abbot R Laptook; Richard A Ehrenkranz; C Michael Cotten; Deanne E Wilson-Costello; Seetha Shankaran; Krisa P Van Meurs; Alexis S Davis; Marie G Gantz; Neil N Finer; Bradley A Yoder; Roger G Faix; Waldemar A Carlo; Kurt R Schibler; Nancy S Newman; Wade Rich; Abhik Das; Rosemary D Higgins; Michele C Walsh
Journal:  Am J Respir Crit Care Med       Date:  2011-03-04       Impact factor: 21.405

2.  Occurrence and severity of bronchopulmonary dysplasia and respiratory distress syndrome after a preterm birth.

Authors:  Jennifer S Landry; Dick Menzies
Journal:  Paediatr Child Health       Date:  2011-08       Impact factor: 2.253

Review 3.  Predictors of bronchopulmonary dysplasia.

Authors:  Andrea Trembath; Matthew M Laughon
Journal:  Clin Perinatol       Date:  2012-09       Impact factor: 3.430

4.  Bronchopulmonary dysplasia: a predictive scoring system for very low birth weight infants. A diagnostic accuracy study with prospective data collection.

Authors:  Ikbel El Faleh; Mohamed Faouzi; Mark Adams; Roland Gerull; Jamel Chnayna; Eric Giannoni; Matthias Roth-Kleiner
Journal:  Eur J Pediatr       Date:  2021-04-06       Impact factor: 3.183

Review 5.  Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study.

Authors:  Wes Onland; Thomas P Debray; Matthew M Laughon; Martijn Miedema; Filip Cools; Lisa M Askie; Jeanette M Asselin; Sandra A Calvert; Sherry E Courtney; Carlo Dani; David J Durand; Neil Marlow; Janet L Peacock; J Jane Pillow; Roger F Soll; Ulrich H Thome; Patrick Truffert; Michael D Schreiber; Patrick Van Reempts; Valentina Vendettuoli; Giovanni Vento; Anton H van Kaam; Karel G Moons; Martin Offringa
Journal:  BMC Pediatr       Date:  2013-12-17       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.